FIG 1.
Study design. aDropouts include death, progression, adverse events, and investigator's decision. CR, complete remission; ECOG, Eastern Cooperative Oncology Group; FOLFOX, fluorouracil, folinic acid, and oxaliplatin; FU/FA, fluorouracil and folinic acid; mCRC, metastatic colorectal cancer; PD, progressive disease; PFS, progression-free survival; Pmab, panitumumab; PR, partial remission; R, random assignment; SD, stable disease; WT, wild type.